Plain-English translation of NCT05350215 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether two medications—atomoxetine and DAW2020—can help reduce the number of breathing interruptions that happen during sleep in people with obstructive sleep apnea (OSA). You would spend two nights in a sleep laboratory: one night taking the study medications and one night taking a placebo (a dummy pill), with about a month between the two nights. The researchers will monitor your sleep and breathing patterns carefully during each night to see if the medication makes a difference.
Obstructive sleep apnea causes your airway to collapse repeatedly during sleep, interrupting your breathing and disrupting your rest. Current treatments like CPAP machines don't work for everyone or aren't tolerated well by some patients. This trial is exploring whether this medication could offer a new way to reduce these dangerous breathing pauses.
You likely qualify if…
You likely don't qualify if…
You would take the first study medication daily for about a week, then come to the sleep laboratory for an overnight visit where researchers monitor your sleep with sensors while you breathe on your own (without a CPAP machine). After about a month, you would return for a second overnight visit, this time taking a placebo pill instead. On both nights, the medical team will check your health and monitor your sleep quality and breathing patterns for at least four hours, with at least half of that time spent sleeping on your back.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States